Article | Published:

A DSTYK mutation activates ERK1/2 signaling to promote intraspinal dissemination in a case of solitary fibrous tumor/hemangiopericytoma


Intracranial solitary fibrous tumors/hemangiopericytomas (SFT/HPCs) are vascular tumors that have a high rate of local recurrence and extracranial metastases. Intradural extramedullary spinal dissemination of intracranial SFT/HPC is extremely rare. There is a paucity of data available to elucidate the molecular mechanisms of intraspinal dissemination of intracranial SFT/HPC. Herein, we presented a case of intracranial SFT/HPC with intraspinal metastasis. The resected tumor specimens were enrolled in a clinical sequencing program, including whole-exome and transcriptome sequencing. By comparing genomic sequencing data of the intracranial tumors with intraspinal metastasis, we established the somatic mutational profiles of these tumors. Clonality analysis revealed a distinct subclonal structure in the intracranial tumor and its intraspinal metastasis, which might reflect the possibility of intratumoral clonal selection and evolution during the process of tumor dissemination. Through bioinformatics analysis and Sanger sequencing validation, a DSTYK mutation (Met296Ile) was identified as a candidate driver of intraspinal metastasis in this SFT/HPC case. Further, an intracranial tumor-derived SFT/HPC cell line, HPC3, was established to explore the mechanisms of the DSTYK mutation in promoting SFT/HPC metastasis. Based on the HPC3 cell model, we found that the DSTYK mutation promoted cell migration and invasion of HPC3 cells via activation of ERK1/2 signaling, which was inhibited by the MEK/ERK inhibitor AZD6244. The DSTYK mutation was also shown to upregulate the expression of two metastasis-related molecules: MMP2 and MMP9 in HPC3 cells; however, this effect was attenuated by AZD6244 treatment. Therefore, the DSTYK mutation may activate ERK1/2/MMP2/9 signaling to promote tumor cell metastasis in SFT/HPC. In conclusion, our study revealed the potential role of DSTYK mutation in the regulation of intraspinal metastasis of SFT/HPC, which might provide new biological insights into this rare disease.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Data availability

All of the data generated or analyzed during this study are included within this published article or within the supplementary materials.


  1. 1.

    Zhang GJ, Zhang LW, Li D, Wu Z, Zhang JT. Analysis of prognostic factors, survival rates, and treatment in anaplastic hemangiopericytoma. World Neurosurg. 2017;104:795–801.

  2. 2.

    Smith K, Talukder A, Kruse EJ. Intracranial hemangiopericytoma: a rare but aggressive tumor. Am Surg. 2015;81:314–5.

  3. 3.

    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.

  4. 4.

    Patel AR, Flores BC, Ban VS, Hatanpaa KJ, Mickey BE, Barnett SL. Intracranial hemangiopericytomas: recurrence, metastasis, and radiotherapy. J Neurol Surg B Skull Base. 2017;78:324–30.

  5. 5.

    Wei G, Kang X, Liu X, Tang X, Li Q, Han J, et al. Intracranial meningeal hemangiopericytoma: recurrences at the initial and distant intracranial sites and extraneural metastases to multiple organs. Mol Clin Oncol. 2015;3:770–4.

  6. 6.

    Ali HS, Endo T, Endo H, Murakami K, Tominaga T. Intraspinal dissemination of intracranial hemangiopericytoma: case report and literature review. Surg Neurol Int. 2016;7(Suppl 40):S1016–20.

  7. 7.

    Liu Q, Zhang C, Yuan J, Fu J, Wu M, Su J, et al. PTK7 regulates Id1 expression in CD44-high glioma cells. Neuro Oncol. 2015;17:505–15.

  8. 8.

    Li H, Durbin R. Fast and accurate long-read alignment with Burrows–Wheeler transform. Bioinformatics. 2010;26:589–95.

  9. 9.

    DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491–8.

  10. 10.

    Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213–9.

  11. 11.

    Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, Källberg M, et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods. 2018;15:591–4.

  12. 12.

    Liu Y, Zhang J, Li L, Yin G, Zhang J, Zheng S, et al. Genomic heterogeneity of multiple synchronous lung cancer. Nat Commun. 2016;7:13200.

  13. 13.

    Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12:e1004873.

  14. 14.

    Shihab HA, Gough J, Cooper DN, Day INM, Gaunt TR. Predicting the functional consequences of cancer-associated amino acid substitutions. Bioinformatics. 2013;29:1504–10.

  15. 15.

    Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357–60.

  16. 16.

    Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc. 2016;11:1650–67.

  17. 17.

    Davidson NM, Majewski IJ, Oshlack A. JAFFA: high sensitivity transcriptome-focused fusion gene detection. Genome Med. 2015;7:43.

  18. 18.

    Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013;45:180–5.

  19. 19.

    Hu X, Chen M, Li Y, Wang Y, Wen S, Jun F. Overexpression of ID1 promotes tumor progression in penile squamous cell carcinoma. Oncol Rep. 2019;41:1091–100.

  20. 20.

    Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G, et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics. 2012;28:423–5.

  21. 21.

    Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012;30:413–21.

  22. 22.

    Roth A, Khattra J, Yap D, Wan A, Laks E, Biele J, et al. PyClone: statistical inference of clonal population structure in cancer. Nat Methods. 2014;11:396–8.

  23. 23.

    Fagerstedt KW, Salonen T, Zhao F, Kytölä S, Böhling T, Andersson LC. Establishment of a spontaneously transformed cell line (JU-PI) from a myxoinflammatory fibroblastic sarcoma. Tumour Biol. 2018;40:1010428318777936.

  24. 24.

    Yang Y, Huang JQ, Zhang X, Shen LF. MiR-129-2 functions as a tumor suppressor in glioma cells by targeting HMGB1 and is down-regulated by DNA methylation. Mol Cell Biochem. 2015;404:229–39.

  25. 25.

    Zhang J, Fu J, Pan Y, Zhang X, Shen L. Silencing of miR-1247 by DNA methylation promoted non-small-cell lung cancer cell invasion and migration by effects of STMN1. Onco Targets Ther. 2016;9:7297–307.

  26. 26.

    Shan N, Shen L, Wang J, He D, Duan C. MiR-153 inhibits migration and invasion of human non-small-cell lung cancer by targeting ADAM19. Biochem Biophys Res Commun. 2015;456:385–91.

  27. 27.

    Jun F, Hong J, Liu Q, Guo Y, Liao Y, Huang J, et al. Epithelial membrane protein 3 regulates TGF-β signaling activation in CD44-high glioblastoma. Oncotarget. 2017;8:14343–58.

  28. 28.

    Hecht I, Natan S, Zaritsky A, Levine H, Tsarfaty I, Ben-Jacob E. The motility-proliferation-metabolism interplay during metastatic invasion. Sci Rep. 2015;5:13538.

  29. 29.

    Sanna-Cherchi S, Sampogna RV, Papeta N, Burgess KE, Nees SN, Perry BJ, et al. Mutations in DSTYK and dominant urinary tract malformations. N Engl J Med. 2013;369:621–9.

  30. 30.

    Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007;6:2209–19.

  31. 31.

    Singh D, Srivastava SK, Chaudhuri TK, Upadhyay G. Multifaceted role of matrix metalloproteinases (MMPs). Front Mol Biosci. 2015;2:19.

  32. 32.

    Nishio K, Motozawa K, Omagari D, Gojoubori T, Ikeda T, Asano M, et al. Comparison of MMP2 and MMP9 expression levels between primary and metastatic regions of oral squamous cell carcinoma. J Oral Sci. 2016;58:59–65.

  33. 33.

    Hayenga HN, Bishop AJ, Wardak Z, Sen C, Mickey B. Intraspinal dissemination and local recurrence of an intracranial hemangiopericytoma: case report. World Neurosurg. 2019;123:68–75.

  34. 34.

    Das A, Singh PK, Suri V, Sable MN, Sharma BS. Spinal hemangiopericytoma: an institutional experience and review of literature. Eur Spine J. 2015;24(Suppl 4):S606–13.

  35. 35.

    Taniura S, Taniguchi M, Mizutani T, Takahashi H. Metastatic hemangiopericytoma to the cauda equina: a case report. Spine J. 2007;7:371–3.

  36. 36.

    Inoue T, Endo T, Nakamura T, Shibahara I, Endo H, Tominaga T. Expression of CD133 as a putative prognostic biomarker to predict intracranial dissemination of primary spinal cord astrocytoma. World Neurosurg. 2018;110:e715–26.

  37. 37.

    Elefante A, Peca C, Del Basso De Caro ML, Russo C, Formicola F, Mariniello G, et al. Symptomatic spinal cord metastasis from cerebral oligodendroglioma. Neurol Sci. 2012;33:609–13.

  38. 38.

    Turtoi A, Blomme A, Castronovo V. Intratumoral heterogeneity and consequences for targeted therapies. Bull Cancer. 2015;102:17–23.

  39. 39.

    Büttner J, Jöhrens K, Klauschen F, Hummel M, Lenze D, Saeger W, et al. Intratumoral morphological heterogeneity can be an indicator of genetic heterogeneity in colorectal cancer. Exp Mol Pathol. 2018;104:76–81.

  40. 40.

    Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520:353–7.

  41. 41.

    Kim TM, Jung SH, An CH, Lee SH, Baek IP, Kim MS, et al. Subclonal genomic architectures of primary and metastatic colorectal cancer based on intratumoral genetic heterogeneity. Clin Cancer Res. 2015;21:4461–72.

  42. 42.

    Zhai W, Lim TK, Zhang T, Phang ST, Tiang Z, Guan P, et al. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat Commun. 2017;8:4565.

  43. 43.

    Xu H, Zhu X, Bao H, Wh Shek T, Huang Z, Wang Y, et al. Genetic and clonal dissection of osteosarcoma progression and lung metastasis. Int J Cancer. 2018;143:1134–42.

  44. 44.

    Kamamoto D, Ohara K, Kitamura Y, Yoshida K, Kawakami Y, Sasaki H. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. J Neurooncol. 2018;139:251–9.

  45. 45.

    Kinslow CJ, Rajpara RS, Wu CC, Bruce SS, Canoll PD, Wang SH, et al. Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system. J Neurooncol. 2017;133:409–17.

  46. 46.

    Peng J, Dong W, Chen Y, Mo R, Cheng JF, Hui CC, et al. Dusty protein kinases: primary structure, gene evolution, tissue specific expression and unique features of the catalytic domain. Biochim Biophys Acta. 2006;1759:562–72.

  47. 47.

    Zha J, Zhou Q, Xu LG, Chen D, Li L, Zhai Z, et al. RIP5 is a RIP-homologous inducer of cell death. Biochem Biophys Res Commun. 2004;319:298–303.

  48. 48.

    Lee JYW, Hsu CK, Michael M, Nanda A, Liu L, McMillan JR, et al. Large intragenic deletion in DSTYK underlies autosomal-recessive complicated spastic paraparesis, SPG23. Am J Hum Genet. 2017;100:364–70.

  49. 49.

    Payton S. Genetics: DSTYK gene linked to urinary tract defects. Nat Rev Urol. 2013;10:492.

  50. 50.

    Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol Cancer Ther. 2018;17:1147–55.

  51. 51.

    Zhong Y, Lu YT, Sun Y, Shi ZH, Li NG, Tang YP, et al. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer. Exp Opin Drug Discov. 2018;13:75–87.

Download references

Author information

Correspondence to Qing Liu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Table S1

Table S2

Table S3

Table S4

Supp Table Legends

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8